CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Strategies for the Development of NK Cell-Based Therapies for Cancer Treatment.
Strategies for the Development of NK Cell-Based Therapies for Cancer Treatment.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T 细胞疗法是一种有前景的癌症治疗方法,但它存在一些缺点。这些缺点促使科学家探索使用更安全的CAR-NK细胞和新的基因修饰,以提高CAR细胞的有效性。在本文中,我们分析了现有的CAR-NK细胞修饰方法,并讨论了涉及CAR-NK疗法的临床试验结果。通常,NK细胞修饰的方法可分为三大类:增强抗肿瘤细胞毒性的策略、改善CAR-NK细胞存活并延长其在体内持续存在的策略,以及提高CAR-NK细胞安全性的策略。本文介绍了CAR-NK细胞对不同肿瘤类型的作用,涉及CAR-NK细胞的临床试验数量逐年增加,迄今为止结果积极。截至2025年9月,所有试验均处于1-2期研究的早期阶段,预计首个CAR-NK产品将在不久的将来获得批准。
CAR-T cell therapy is a promising method of cancer treatment, but it has some disadvantages. These disadvantages have led scientists to explore the use of safer CAR-NK cells and new genetic modifications in order to improve the effectiveness of CAR cells. In this paper, we analyze existing approaches to modifying CAR-NK cells and discuss the results of clinical trials involving CAR-NK therapies.
Conventionally, approaches to NK cell modification can be divided into three main groups: strategies to enhance antitumor cytotoxicity, strategies to improve the survival of CAR-NK cells and prolong their persistence in the body, and strategies to increase the safety of CAR-NK cells.
The effects of CAR-NK cells on different tumor types are presented, and the number of clinical trials involving CAR-NK cells has been increasing every year, with positive results so far. As of September 2025, all the trials are in the early 1-2 stages of research, and it is expected that the first CAR-NK product will be approved in the near future.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。